![Medical trial shows rare result as cancer vanishes in all patients](https://www.thehindu.com/news/national/nv1cp7/article65504617.ece/alternates/LANDSCAPE_615/oncologists.jpg)
Medical trial shows rare result as cancer vanishes in all patients
The Hindu
None of the participants in the medical trial showed severe side effects as well
In a surprising result for an ongoing medical trial, 12 rectal cancer patients were completely healed of the disease after taking a drug for six months. The patients underwent a series of medical exams — physical exam, endoscopy, bioscopy, PET scans and MRI scans — and none of the reports showed any signs of the tumour.
The findings were published in a paper in the New England Journal of Medicine. The paper lists the names of 32 authors.
The initial purpose of this study was listed to find out whether the study drug, TSR-042 (commonly called dostarlimab), followed by standard chemoradiotherapy and standard surgery is an effective treatment for advanced deficient MisMatch Repair (dMMR) solid tumours.
The medical trial was supported by the Simon and Eve Colin Foundation, GlaxoSmithKline, Stand Up to Cancer, Swim Across America, and the National Cancer Institute of the National Institutes of Health.
Participants of the trial with mismatch repair-deficient stage II or III rectal adenocarcinoma were given the drug every three weeks, for six months. According to the initial plan, the treatment was to be followed by standard chemotherapy and surgery, and patients who had a clinical complete response would proceed without both. After at least six months of follow-up, all 12 patients showed a clinical complete response with no signs of the tumour.
At the time of publication of the paper (June 5, 2022), no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up that ranged from six to 25 months.
“It’s what cancer doctors’ dreams are made of,” Dr. Andrea Cercek, a co-author of the paper and an oncologist at the Memorial Sloan Kettering Cancer Centre in New York, said while speaking to CNN. Explaining how the drug used in the trial works, she said, “Dostarlimab works by unlocking the body’s natural immune system to fight cancer. When we give immunotherapy like [with] dostarlimab, it ramps up the immune system so that it sees cancer and gets rid of it,” she added. “What’s remarkable here is that it completely eliminated cancer. The tumours just vanished.”
![](/newspic/picid-1269750-20240612071728.jpg)
Last year, six women entrepreneurs who are behind handcrafted brands in the city came together to create the Busy Fingers group. Having met through common friends, and their shared love for all things handmade, they went on to host their first pop-up, and are now gearing up for its second edition this weekend.
![](/newspic/picid-1269750-20240610035159.jpg)
Even as prominent ecotourism destinations in Kozhikode offer visitors a feast for the eyes during the monsoon season, the district is yet to witness promotional activities by the Tourism department or the District Tourism Promotion Council. On the other hand, private tourism entrepreneurs are benefiting from the season by offering visitors reduced tariffs for accommodation and recreational activities.